A Bayesian model to analyse the association of comorbidities with biosimilar treatment retention in a non-medical switch scenario in patients with inflammatory rheumatic musculoskeletal diseases.
Imke RedekerStefan MoustakisStyliani TsiamiXenofon BaraliakosDavid KieferIoana AndreicaBjörn BuehringJüergen BraunUta KiltzPublished in: Arthritis research & therapy (2024)
In a non-medical switch scenario of RMD patients, there was no evidence for a considerable difference in ABP retention rates over 6 months between comorbidity groups.